Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AG-181 in Healthy Participants
Conditions
Interventions
AG-181
Placebo
Locations
1
United States
ICON 1255 East 3900 South
Salt Lake City, Utah, United States
Start Date
February 20, 2024
Primary Completion Date
October 9, 2025
Completion Date
October 9, 2025
Last Updated
December 23, 2025
NCT07310264
NCT06342713
NCT07472361
NCT06823947
NCT06649110
NCT07240675
Lead Sponsor
Agios Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions